Fresenius Signs Exclusive WuXi Biologics Biosimilars Deal
The agreement gives Fresenius access to up to 37 biosimilar candidates, with potential expansion to up to 66 molecules. Fresenius retains exclusive global commercialization rights; 2026 guidance is unchanged.
Fresenius entered an exclusive development agreement with WuXi Biologics, giving access to up to 37 biosimilar candidates and potential expansion to up to 66 molecules. Fresenius keeps exclusive global commercialization rights; 2026 guidance unchanged.Material DetailsContext by AI AnalystThis is an…